Suppr超能文献

1,25-二羟维生素D3反应性和抗性黑色素瘤细胞中维生素D内分泌系统的体外比较

In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.

作者信息

Reichrath Jörg, Rech Martin, Moeini Maryam, Meese Eckart, Tilgen Wolfgang, Seifert Markus

机构信息

Department of Dermatology , The Saarland University Hospital, Homburg Germany.

出版信息

Cancer Biol Ther. 2007 Jan;6(1):48-55. doi: 10.4161/cbt.6.1.3493.

Abstract

We studied effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], its analog seocalcitol (EB 1089), and 25-hydroxyvitamin D3 [25(OH)D3], on the growth of seven melanoma cell lines. While three cell lines (MeWo, SK-Mel-28, SM) responded to antiproliferative effects of active vitamin D analogs, the others (SK-Mel-5, SK-Mel-25, IGR, MeUuso) were resistant. A strong induction (7000-fold) of 1,25-dihydroxyvitamin D-24-hydroxylase (24OHase, CYP24) mRNA was detected in responsive cell lines along with 1,25(OH)2D3-treatment, indicating functional integrity of vitamin D receptor (VDR)-mediated transcription. In contrast, induction of 24OHase was much lower in resistant melanoma cells (70-fold). VDR mRNA was induced up to 3-fold both in responsive and resistant cell lines along with 1,25(OH)2D3-treatment. RNA for vitamin D-activating enzymes vitamin D-25-hydroxylase (25OHase, CYP27A1) and 25-hydroxyvitamin D-lalpha-hydroxylase (lalphaOHase, CYP27B1) was detected in all melanoma cell lines analyzed, additionally we show splicing variants of lalphaOHase in SK-Mel-28 cells. Expression of 250Hase and laOHase was marginally modulated along with treatment. Proliferation of melanoma cells was not inhibited by treatment with 25(OH)D3, indicating no significant stimulation of endogeneous production of antiproliferative acting 1,25(OH)2D3. In conclusion, we characterize the vitamin D endocrine system in melanoma cells and demonstrate that the majority of melanoma cell lines analyzed is resistant to antiproliferative effects of 1,25(OH)2D3. It can be speculated that these alterations are of importance for pathogenesis and growth of metastasizing malignant melanoma. Additionally, our findings indicate that only a minority of cases with metastasizing melanoma may represent a promising target for palliative treatment with new vitamin D analogs that exert little calcemic side effects or for pharmacological modulation of 1,25(OH)2D3-synthesis/metabolism.

摘要

我们研究了1,25 - 二羟基维生素D3 [1,25(OH)2D3]、其类似物司骨化醇(EB 1089)和25 - 羟基维生素D3 [25(OH)D3]对七种黑色素瘤细胞系生长的影响。虽然三种细胞系(MeWo、SK - Mel - 28、SM)对活性维生素D类似物的抗增殖作用有反应,但其他细胞系(SK - Mel - 5、SK - Mel - 25、IGR、MeUuso)具有抗性。在用1,25(OH)2D3处理的反应性细胞系中,检测到1,25 - 二羟基维生素D - 24 - 羟化酶(24OHase,CYP24)mRNA有强烈诱导(7000倍),表明维生素D受体(VDR)介导的转录功能完整。相比之下,抗性黑色素瘤细胞中24OHase的诱导要低得多(70倍)。在用1,25(OH)2D3处理的反应性和抗性细胞系中,VDR mRNA均被诱导高达3倍。在所有分析的黑色素瘤细胞系中均检测到维生素D激活酶维生素D - 25 - 羟化酶(25OHase,CYP27A1)和25 - 羟基维生素D - 1α - 羟化酶(1αOHase,CYP27B1)的RNA,此外,我们在SK - Mel - 28细胞中展示了1αOHase的剪接变体。250Hase和1αOHase的表达随处理仅有轻微调节。用25(OH)D3处理并未抑制黑色素瘤细胞的增殖,表明对具有抗增殖作用的1,25(OH)2D3的内源性产生没有显著刺激。总之,我们对黑色素瘤细胞中的维生素D内分泌系统进行了表征,并证明所分析的大多数黑色素瘤细胞系对1,25(OH)2D3的抗增殖作用具有抗性。可以推测,这些改变对转移性恶性黑色素瘤的发病机制和生长具有重要意义。此外,我们的研究结果表明,只有少数转移性黑色素瘤病例可能是用几乎没有高钙血症副作用的新型维生素D类似物进行姑息治疗或对1,25(OH)2D3合成/代谢进行药理学调节的有希望的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验